Today: 29 June 2026
Dow Jones Falls as Bond Yields Signal Trouble for Bulls
19 May 2026
2 mins read

Dow Jones Falls as Bond Yields Signal Trouble for Bulls

NEW YORK, May 19, 2026, 11:22 EDT

Dow drops as yields, oil push stocks down
The Dow Jones Industrial Average lost ground Tuesday morning, down 249.36 points, or 0.5%, to 49,436.76 by 10:55 a.m. EDT. Treasury yields moved higher and concerns about oil-driven inflation grew, dragging Wall Street lower. S&P 500 declined 0.77%. Nasdaq Composite was off 1.28%, with selling pressure showing up outside of the Dow’s 30 stocks.

Stocks were trading in the regular NYSE hours. The NYSE core session is open from 9:30 a.m. to 4:00 p.m. ET. According to the exchange’s 2026 holiday calendar, the next scheduled full market holiday is Memorial Day on Monday, May 25.

Bonds are calling the shots again. The 10-year Treasury yield hit 4.663% on Monday, marking its highest since January 2025, according to Reuters. That rate is a key barometer for U.S. government borrowing and sets the baseline for other credit costs. Higher yields like this often weigh on equities by making future company profits worth less and driving up borrowing costs for everyone from corporations to consumers.

Oil prices held above $110 for Brent crude, despite a dip. Investors kept an eye on Middle East risks and concerns that stubborn energy costs might keep inflation high. “The market is returning to macroeconomic and geopolitical risks,” Swissquote Bank senior analyst Ipek Ozkardeskaya told Reuters. Reuters

Dow climbed 159.95 points to 49,686.12 on Monday, but the S&P 500 and Nasdaq finished lower. Weakness followed into Tuesday. Burns McKinney, a portfolio manager at NFJ Investment Group, told Reuters that “oil prices” were driving day-to-day market moves, citing inflation concerns as Strait of Hormuz risks remain. Reuters

3M and Sherwin-Williams pulled down the Dow, with Goldman Sachs, Amazon and Home Depot also pressuring the index, MarketWatch reported. The Dow is price-weighted, so a $1 change in a higher-priced stock has more impact on the index than the same dollar amount in a lower-priced name.

Home Depot focused on the consumer in the first quarter. The company said sales were $41.8 billion, a gain of 4.8% over last year. Comparable sales were up 0.6%. CEO Ted Decker said demand looked much like 2025 even with ongoing “consumer uncertainty and housing affordability pressure.” Home Depot left its fiscal 2026 guidance unchanged. Home Depot Investor Relations

Home Depot set the stage with its numbers, but the read-through across competitors was mixed. Lowe’s and Walmart will drop their results later this week. Nvidia’s report on Wednesday is lining up as the big test for the AI trade, and whether it can keep pushing the Nasdaq and S&P 500 higher.

But there’s a risk on both sides. If oil or Treasury yields drop fast, that might give the Dow some relief. But if they push higher again, traders could see that as more proof inflation stays hot and the Fed can’t cut rates. Brent was at $110.50, and the 10-year yield was at 4.678% late morning, according to Investing.com.

The Dow isn’t acting like the usual haven from tech losses. Lately it’s tracking rates, crude and spending instead. Not much relief on the screen—yields stay up, earnings aren’t the whole picture, and the market is still waiting on fresh policy signals.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • AbbVie Stock Surges, Boosting Valuation of $10.9 Billion Apogee Acquisition
    June 28, 2026, 6:38 PM EDT. AbbVie Inc. shares climbed 4.2% to a 52-week high of $253.35 on June 26, lifting the company's market value by approximately $65 billion since June 18. This surge is nearly six times the $10.9 billion cash price AbbVie is paying for Apogee Therapeutics. The acquisition, financed through debt, includes Apogee's late-stage IL-13 antibody zumilokibart for atopic dermatitis. Despite a 49% premium paid over Apogee's June 18 close, AbbVie expects a reduced adjusted earnings per share (EPS) in 2026 and 2027, with accretion only anticipated by 2032. Investors appear focused on AbbVie's long-term immunology growth, with key drugs Skyrizi and Rinvoq generating $6.6 billion in Q1 revenue. AbbVie's CEO described the deal as creating significant long-term shareholder value.

Latest articles

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

29 June 2026
Kroger (NYSE:KR) faces scrutiny after a USDA alert flagged mislabeled Private Selection Honey Dijon chicken in nine states, but with no confirmed adverse reactions and the product already off shelves, the stock closed Friday at $57.73, down 5 cents; any expansion of affected lots or confirmed cases could alter risk for investors.
Evolution stock jumps on €2 billion move
Previous Story

Evolution stock jumps on €2 billion move

Constellation Software Stock Climbs as Broader Canadian Market Loses Ground
Next Story

Constellation Software Stock Climbs as Broader Canadian Market Loses Ground

Go toTop